In early 2022, a competitive application process was opened for ID fellowship programs to participate in the pilot. Eleven ID fellowship programs were selected to participate in the first year of the pilot. The participating programs are Emory University School of Medicine, Massachusetts General Hospital/Brigham and Women’s Hospital, Rush University Medical Center/Cook County Health, Stanford Medicine, University of New Mexico Health Sciences Center, University of North Carolina-Chapel Hill, University of Washington, University of Wisconsin – Madison, Vanderbilt University Medical Center, Weill Cornell/New York Presbyterian, and West Virginia University.
The competitive application process to become part of the joint fellowship has closed for calendar year 2023. Selected ID fellowship programs were notified in summer 2023. Public announcements will follow in fall 2023.
IDSA and CDC expect to expand the number of participating programs in future years, however no specific date is set at this time to further expand the pilot. Information about further expansion will be shared through ID/EIS newsletters, on this website, and through direct messages to ID Fellowship Program Directors.
Learn more about applying to be part of the pilot and how the joint fellowship works in the sections below.
The joint ID/EIS fellowship program may expand in future years, through a competitive application process. The application period for 2023 has closed and selected programs were notified in summer 2023. Though a timeline for further expansion is not currently defined, programs that applied previously but were not selected are strongly encouraged to apply again and will be able to access historical application information.
The number of additional ID fellowship programs added in future years will depend on CDC funding as well as program and applicant interest. Any ID fellowship program interested in the joint ID/EIS fellowship can be considered as long as it can provide appropriate support to fellows, demonstrate strong relationships with health departments and focus on public health.
Currently the joint ID/EIS fellowship program is open to adult ID fellowship programs only. The feasibility of including pediatric ID fellowship programs is being explored.
Program Requirements: The joint ID/EIS fellowship program is compatible with two-year adult ID fellowship programs. No changes to ID fellowship curriculum or focus are needed to participate in the joint fellowship. Programs must participate in the all-in Match.
During the pilot phase, the joint fellowship will accept applications from U.S. citizens and permanent residents.
The EIS fellowship program has a strong focus on public health, so ID fellowship programs with opportunities for fellows to conduct public health research and which often engage with state and local health departments are encouraged to apply for participation in future years of the pilot.
Memorandum of Understanding with IDSA: Participating ID fellowship programs must adhere to a Memorandum of Understanding which outlines expectations for the ID fellowship programs and the support IDSA will provide during the pilot. While some small adjustments may be feasible to the language, IDSA prefers to minimize the changes to the document. Please review the MOU with your legal or contracts team to ensure that it is acceptable to your program prior to submitting the application. Reach out to IDEISfellowship@idsociety.org with any questions about the MOU.
Social Media/Online Promotion: The joint ID/EIS fellowship is a new opportunity, and marketing support is critical for success. Participating ID fellowship programs must be willing to promote the joint fellowship program through their social media and on their website. IDSA provides sample post copy and promotional materials to participating ID fellowship programs. IDSA will ask for periodic updates on the number of posts made about the joint fellowship program, for reporting purposes.
Pilot Program Feedback: ID fellowship programs participating in the pilot will be asked to provide feedback.
The joint ID/EIS fellowship program will use a parallel application process. The joint fellowship will follow existing application timelines for ID and EIS fellowships (EIS timeline). Applicants will complete the EIS application through the EIS application portal, and ID applications will be submitted through ERAS. Both EIS and ID fellowship programs will review applicants through their usual processes. ID programs participating in the pilot will need to add a joint track in ERAS and NRMP to facilitate the application and Match processes. If unfilled in the Match, the joint track opening will roll over to the program’s traditional ID track.
ID fellowship programs are expected to review candidates for the joint ID/EIS fellowship under the same criteria as non-joint applicants. Only applicants who meet standards for both programs will be accepted to the joint ID/EIS fellowship. Acceptance to one program does not guarantee acceptance to another program or to the joint fellowship program.
Joint applicants (as well as ID fellowship programs participating in the pilot) will learn of their EIS application’s acceptance status from CDC before completing the Match process. Joint applicants will rank the joint track or a stand-alone ID program depending on their preferences.
CDC manages the EIS placement of joint fellows. The EIS placement for accepted joint fellows will be determined at the EIS conference during the first year of ID fellowship. A placement may be available regionally near the ID fellowship program or in Atlanta.
To sign up for updates on the Joint ID/EIS Fellowship Program, submit email here. Please indicate if you are a potential applicant or with an ID Fellowship program.
The joint ID/EIS fellowship pilot program is funded by a cooperative agreement with the Centers for Disease Control and Prevention (grant number NU50CK000574). The Centers for Disease Control and Prevention is an agency within the Department of Health and Human Services (HHS). The information on this page does not necessarily represent the policy of CDC or HHS, and should not be considered an endorsement by the Federal Government.
